Denosumab Promising for TDT - Induced Osteoporosis Treatment
Higher percentage increase of L1 to L4 and wrist bone mineral density with DMN, reduction in pain (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 13, 2018 Category: Cancer & Oncology Tags: Endocrinology, Family Medicine, Gynecology, Internal Medicine, Oncology, Orthopedics, Pharmacy, Journal, Source Type: news
Denosumab Promising for TDT-Induced Osteoporosis Treatment
TUESDAY, Nov. 13, 2018 -- Denosumab (DNM), a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL), may be beneficial for managing transfusion-dependent thalassemia (TDT)-induced osteoporosis,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 13, 2018 Category: Pharmaceuticals Source Type: news
Denosumab not cost effective for treatment of bone metastases
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2018 Category: Drugs & Pharmacology Source Type: news
Amgen Reports Third Quarter 2018 Financial Results
THOUSAND OAKS, Calif., Oct. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2018. Key results include:
Total revenues increased 2 percent versus the third quarter of 2017 to $5.9 billion.
Product sales grew 1 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) showed double-digit growth.
GAAP earnings per share (EPS) increased 4 percent to $2.86 driven by higher total revenues, a lower tax rate and lower weighted-average shares outstanding.
...
Source: Amgen News Release - October 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Can Rare Rebound Fractures After Denosumab Therapy Be Avoided? Can Rare Rebound Fractures After Denosumab Therapy Be Avoided?
Two studies suggest rare rebound vertebral fractures after stopping denosumab may be averted by giving a potent bisphosphonate and not continuing aromatase inhibitors beyond 6 months of stopping.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
ONJ With Bone-Modifying Agents in Breast Cancer Patients ONJ With Bone-Modifying Agents in Breast Cancer Patients
Osteonecrosis of the jaw was reported in metastatic breast cancer patients treated with bone-modifying agents; the incidence was higher with denosumab compared with bisphosphonates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Amgen Reports Second Quarter 2018 Financial Results
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include:
Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion.
Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth.
GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding.
...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Adjuvant Denosumab Fails to Reduce Recurrences, Deaths in Early Breast Cancer
The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures
THOUSAND OAKS, Calif., June 8, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) h... Biopharmaceuticals, Regulatory Amgen, Prolia , denosumab, osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 8, 2018 Category: Pharmaceuticals Source Type: news
European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures
THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment.1
"We are pl...
Source: Amgen News Release - June 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Denosumab subsidised by PHARMAC for osteoporosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news
New Denosumab Indication; Seafood & Fertility; World Thyroid Day
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - May 25, 2018 Category: Pediatrics Source Type: news
FDA Approves Denosumab for Steroid-Induced Osteoporosis FDA Approves Denosumab for Steroid-Induced Osteoporosis
The US FDA has approved denosumab (Prolia, Amgen) for treatment of glucocorticoid-induced osteoporosis. European regulators recently green-lighted the same indication.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Approves Prolia ® (Denosumab) For Glucocorticoid-Induced Osteoporosis
Fifth Indication for Prolia for Men and Women at High Risk of Fracture Receiving Systemic Glucocorticoid Therapy
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data from a Phase 3 st...
Source: Amgen News Release - May 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 21, 2018 Category: Drugs & Pharmacology Source Type: news
